Literature DB >> 22294221

Animal models of multiple myeloma and their utility in drug discovery.

Richard A Campbell1, James R Berenson.   

Abstract

To evaluate potential new therapies and targets for treating multiple myeloma (MM), reproducible, biologically relevant in vivo models are required. Preclinical in vivo models of human MM allow investigators to evaluate novel therapies alone and in combination and quickly translate these results to the clinic where patients directly benefit, whether in the form of a new clinical trial, new doses and schedules, or new drug combinations. Presented in this unit are protocols for generating and maintaining a human extramedullary MM tumor in mice. Additionally, the extramedullary tumor can be excised and digested into a single-cell suspension and the human MM cells injected into mice subcutaneously, intravenously, or intratibially. Once these tumors are generated, they can be used to evaluate novel anti-MM agents and other therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 22294221     DOI: 10.1002/0471141755.ph1409s40

Source DB:  PubMed          Journal:  Curr Protoc Pharmacol        ISSN: 1934-8282


  3 in total

1.  Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.

Authors:  Manh-Cuong Vo; Seoyun Yang; Sung-Hoon Jung; Tan-Huy Chu; Hyun-Ju Lee; Thangaraj Jaya Lakshmi; Hye-Seong Park; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Front Immunol       Date:  2018-08-03       Impact factor: 7.561

2.  Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.

Authors:  Sarah L Pogue; Tetsuya Taura; Mingying Bi; Yong Yun; Angela Sho; Glen Mikesell; Collette Behrens; Maya Sokolovsky; Hussein Hallak; Moti Rosenstock; Eric Sanchez; Haiming Chen; James Berenson; Anthony Doyle; Steffen Nock; David S Wilson
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

3.  Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma.

Authors:  Manh-Cuong Vo; Sung-Hoon Jung; Tan-Huy Chu; Hyun-Ju Lee; Thangaraj Jaya Lakshmi; Hye-Seong Park; Hyeoung-Joon Kim; Joon Haeng Rhee; Je-Jung Lee
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.